Management of fetal endocrine disorders

Growth Hormone and IGF Research

Volumn 13, Issue SUPPL. A, 2003, Pages

  Hughes, I A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Adrenals; Congenital adrenal hyperplasia (CAH); Enzymes; Fetus; Intrauterine growth retardation; Placenta; Steroids; Thyroid

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID; LIOTHYRONINE; STEROID; THYROID HORMONE; THYROTROPIN; THYROXINE; TIRATRICOL;

ADRENAL SUPPRESSION; ARTICLE; CONGENITAL ADRENAL HYPERPLASIA; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; ENDOCRINE DISEASE; FETUS; FETUS DISEASE; FETUS GROWTH; FREE THYROXINE INDEX; GOITER; GRAVES DISEASE; HUMAN; HYPOCALCEMIA; INTRAUTERINE GROWTH RETARDATION; LOW BIRTH WEIGHT; MACROSOMIA; MATERNAL NUTRITION; POSTMATURITY; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; THYROID DISEASE; THYROID FUNCTION TEST; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL; VIRILIZATION;

EID: 0141631439     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1096-6374(03)00056-X     Document Type: Article

References (44)

1. J.H. Lazarus, A. Kokandi, Thyroid disease in relation to pregnancy: a decade of change, Clin. Endocrinol. 53 (2000) 265-278.
2. U.S. Maziukievicz, G.N. Burrow, Hyperthyroidism in pregnancy: diagnosis and treatment, Thyroid 9 (1999) 647-652.
3. V.J. Pop, J.L. Kuijpens, A.L. van Baar, G. Verkerk, M.M. van Son, J.J. de Vijlder, T. Vulsma, W.M. Wiersinga, H.A. Drexhage, H.L. Vader, Low maternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor development in infancy, Clin. Endocrinol. 50 (1999) 149-155.
4. J.E. Haddow, G.E. Palomaki, W.C. Allan, J.R. Williams, G.J. Knight, J. Gagnon, C.E. O'Heir, M.L. Mitchell, R.J. Hermos, S.E. Waisbren, J.D. Faix, R.Z. Klein, Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child, N. Engl. J. Med. 341 (1999) 549-555.
5. R.Z. Klein, J.E. Haddow, J.D. Faix, R.S. Brown, R.J. Hermos, A. Pulkkinen, M.L. Mitchell, Prevalence of thyroid deficiency in pregnant women, Clin. Endocrinol. 35 (1991) 41-46.
6. R.Z. Klein, J.D. Sargent, P.R. Larsen, S.E. Waisbren, J.E. Haddow, M.L. Mitchell, Relation of severity of maternal hypothyroidism to cognitive development of offspring, J. Med. Screening 8 (2001) 18-20.
7. F. Perrotin, C. Sembeley-Taveau, G. Haddad, C. Lyonnais, J. Lausac, G. Body, Prenatal diagnosis and early in utero management of fetal dyshormonogenetic goiter, Eur. J. Obstet. Gynecol. Reprod. Biol. 94 (2001) 309-314.
8. P. Agrawal, A. Ogilvy-Stuart, C. Lees, Intrauterine diagnosis and management of congenital goitrous hypothyroidism, Ultrasound Obstet. Gynecol. 19 (2002) 501-505.
9. U. Nicolini, E. Venegoni, B. Acaia, D. Cortelazzi, P. Beck-Peccoz, Prenatal treatment of fetal hypothyroidism: is there more than one option? Prenat. Diagn. 16 (1996) 443-448.
10. D. Cortelazzi, P.S. Morpuro, P. Zamperini, D.A. Fisher, P. Beck-Peccoz, S.Y. Wu, Maternal compound W serial measurements for the management of fetal hypothyroidism, Eur. J. Endocrinol. 141 (1999) 570-578.
11. K. Sun, K. Yang, J.R.G. Challis, Differential expression of 11β-hydroxysteroid dehydrogenase types 1 and 2 in human placenta and fetal membranes, J. Clin. Endocrinol. Metab. 82 (1997) 300-305.
12. P.C. White, T. Mune, A. K. Agarwal, 11β-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess, Endocr. Rev. 18 (1997) 135-156.
13. S. Kitanaka, A. Tanae, I. Hibi, Apparent mineralocorticoid excess due to 11β-hydroxysteroid deficiency: a possible cause of intrauterine growth retardation, Clin. Endocrinol. 44 (1996) 353-359.
14. K. Albertsson-Wikland, J. Karlberg, Natural growth in children born small for gestational age with and without catch-up growth, Acta Paed. 399 (Suppl.) (1994) 64-70.
15. K. Karlberg, K. Albertsson-Wikland, Growth in full-term small-for-gestational age infants: from birth to final height, Pediatr. Res. 38 (1995) 733-739.
16. J.M. Reimisch, N.G. Simon, W.G. Karow, R. Gandelman, Prenatal exposure to prednisone in humans and animals retards intrauterine growth, Science 202 (1978) 436-438.
17. P.M. Stewart, F. Rogerson, J.I. Mason, Type 2 11β-hydroxysteroid dehydrogenase in human placenta and fetal membranes: its relationship to birth weight and putative role in fetal adrenal steroidogenesis, J. Clin. Endocrinol. Metab. 80 (1995) 885-890.
18. R. Benediktsson, A.A. Calder, C.R.W. Edwards, J.R. Seckl, Placental 11β-hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure, Clin. Endocrinol. 46 (1997) 161-166.
19. M. Shams, M.D. Kilby, D.A. Somerset, A.J. Howie, A. Gupta, P.J. Wood, M. Afnan, P.M. Stewart, Ontogeny of placental 11β-hydroxysteroid dehydrogenase type 2 in human pregnancy and reduced expression in intrauterine growth retardation, Hum. Reprod. 13 (1998) 799-804.
20. C.L. McTernan, N. Draper, H. Nicholson, S.M. Chalder, P. Driver, M. Hewison, M.D. Kilby, P.M. Stewart, Reduced placental 11β-hydroxysteroid dehydrogenase type 2 mRNA levels in human pregnancies complicated by intrauterine growth retardation: an analysis of possible mechanisms, J. Clin. Endocrinol. Metab. 86 (2001) 4979-4983.
21. M.M. Grumbach, R.J. Auchus, Estrogen: consequences and implications of human mutations in synthesis and action, J. Clin. Endocrinol. Metab. 84 (1999) 4677-4694.
22. A. Hernandez-Martin, R. Gonzalez- Sarmiento, P. De Unamuno, X-linked icthyosis: an update, Br. J. Dermatol. 141 (1999) 617-627.
23. E.R. Simpson, S.R. Davis, Minireview: aromatase and the regulation of estrogen biosynthesis - some new perspectives, Endocrinology 142 (2001) 4589-4594.
24. P.A. Benn, Advances in prenatal screening for Down syndrome: I. General principles and second trimester testing, Clin. Chim. Acta 323 (2002) 1-16.
25. D. Newby, D.A. Aitken, A.G. Howatson, J.M. Connor, Placental synthesis of oestriol in Down's syndrome pregnancies, Placenta 21 (2000) 263-267.
26. M. Shozu, K. Akasofu, T. Harada, Y. Kubota, A new cause of female pseudohermaphroditism: placental aromatase deficiency, J. Clin. Endocrinol. Metab. 72 (1991) 560-566.
27. A. Morishima, M.M. Grumbach, E.R. Simpson, C. Fisher, K. Qin, Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens, J. Clin. Endocrinol. Metab. 80 (1995) 3689-3698.
28. P.E. Mullis, N. Yoshimura, B. Kuhlmann, K. Lippuner, P. Jaeger, H. Harada, Aromatase deficiency in a female who is compound heterozygote for two new point mutations in the P450arom gene. Impact of estrogens on hypergonadotrophic hypogonadism, multicystic ovaries, and bone densitometry in childhood, J. Clin. Endocrinol. Metab. 82 (1997) 1739-1745.
29. U. Meinhardt, P.E. Mullis, The aromatase cytochrome P-450 and its clinical impact, Horm. Res. 57 (2002) 145-152.
30. F.G. Riepe, N. Krone, M. Viemann, C.-J. Partsch, W.G. Sippell, Management of congenital adrenal hyperplasia: results of the ESPE questionnaire, Horm. Res. 58 (2002) 196-205.
31. B.I. Cerame, R.S. Newfield, L. Pascoe, K.M. Curnow, S. Nimkarn, T.F. Roe, M.I. New, R.C. Wilson, Prenatal diagnosis and treatment of 11β-hydroxylase deficiency congenital adrenal hyperplasia resulting in normal female genitalia, J. Clin. Endocrinol. Metab. 84 (1999) 3129-3134.
32. C.R. Parker Jr., Dehydroepiandrosterone and dehydroepiandrosterone sulphate production in the human adrenal during development and ageing, Steroids 64 (1999) 640-647.
33. C.R. Parker Jr., B.R. Carr, C.A. Winkel, M.L. Casey, E.R. Simpson, P.C. MacDonald, Hypercholesterolemia due to elevated low density lipoprotein-cholesterol in newborns with anencephaly and adrenal atrophy, J. Clin. Endocrinol. Metab. 57 (1983) 37-43.
34. C.R. Parker Jr., M.W. Atkinson, J. Owen, W.W. Andrews, Dynamics of the fetal adrenal, cholesterol and apolipoprotein B response to antenatal betamethasone therapy, Am. J. Obstet. Gynecol. 174 (1996) 562-566.
35. P.C. White, P.W. Speiser, Congenital adrenal hyperplasia due to 21-hydroxylase deficiency, Endocr. Rev. 21 (2000) 245-291.
36. S.M. Baumgartner-Parzer, E. Schulze, W. Waldhäusl, S. Pauschenwein, S. Rondot, P. Nowotny, K. Meyer, H. Frisch, F. Waldhauser, H. Vierhapper, Mutational spectrum of the steroid 21-hydroxylase gene in Austria: identification of a novel missense mutation, J. Clin. Endocrinol. Metab. 86 (2001) 4771-4775.
37. L.B. Dain, N.D. Buzzalino, A. Oneto, S. Belli, M. Stivel, T. Pasqualini, C. Minutolo, E.H. Charreau, L.G. Alba, Classical and nonclassical 21-hydroxylase deficiency: a molecular study of Argentine patients, Clin. Endocrinol. 56 (2002) 239-245.
38. I.A. Hughes, Congenital adrenal hyperplasia - a continuum of disorders, Lancet 352 (1998) 752-754.
39. S. Lajic, A. Wedell, T.H. Bui, E.M. Ritzen, M. Holst, Long-term somatic follow-up of prenatally treated children with congenital adrenal hyperplasia, J. Clin. Endocrinol. Metab. 83 (1998) 3872-3880.
40. M.I. New, A. Carlson, J. Obeid, I. Marshall, M.S. Cabrera, A. Goseco, K. Lin-Su, A.S. Putnam, J.Q. Wei, R.C. Wilson, Prenatal diagnosis for congenital adrenal hyperplasia in 532 pregnancies, J. Clin. Endocrinol. Metab. 86 (2001) 5651-5657.
41. E.M. Ritzen, Prenatal dexamethasone treatment of fetuses at risk for congenital adrenal hyperplasia: benefits and concerns, Semin. Neonatol. 6 (2001) 357-362.
42. S.X. Shen, M.C. Young, M. Hinohosa-Sandoval, I.A. Hughes, 170H-progesterone response to acute dexamethasone administration in congenital adrenal hyperplasia, Horm. Res. 32 (1989) 136-141.
43. P.E. Clayton, W.L. Miller, S.E. Oberfield, E.M. Ritzen, W.G. Sippell, P.W. Speiser, Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology, J. Clin. Endocrinol. Metab. 87 (2002) 4048-4053.
44. S.M. Woodall, B.H. Breier, B.M. Johnston, N.S. Bassett, R. Barnard, P.D. Gluckman, Administration of growth hormone or IGF-1 to pregnant rats on a reduced diet throughout pregnancy does not prevent fetal intrauterine growth retardation and elevated blood pressure in adult offspring, J. Endocrinol. 163 (1999) 69-77.